VistaGen Therapeutics Cultura de la Empresa

Dr. Mark A. Smith, M.D., Ph.D. has been the Chief Medical Officer of VistaGen Therapeutics, Inc. since June 18, 2016. Dr. Smith is a Research Psychiatrist with more than 20 years of experience in basic research and CNS drug development from the lab bench through clinical proof of concept studies. He has been a successful project leader in both discovery and development resulting in approximately 20 investigational new drugs (INDs). Dr. Smith has directed clinical trials aimed at depression, bipolar disorder, anxiety, schizophrenia, Alzheimer's, ADHD and agitation in Phase 1 through Phase 2b and has vast knowledge and expertise in drug discovery and development, translational neuroscience, clinical trial design and regulatory interactions. Dr. Smith received his Bachelor's degree and Master of Science from Yale University, his Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California, San Diego and completed his residency in the Department of Psychiatry at Duke University Medical Center.

Dr. H. Ralph Snodgrass, Ph.D. Founded VistaGen Therapeutics, Inc. in 1998 and has been its President and Chief Scientific Officer since May 2011 and served as its Chief Executive Officer. Dr. Snodgrass served as the Chief Scientific Officer and Vice President of Research of Progenitor, Inc. He was the primary architect of the discovery platform that raised substantial funds and enabled a successful initial public stock offering based upon a technology platform involving molecular biology, bioinformatics, hematopoiesis and immunology. Dr. Snodgrass is the inventor on eleven issued, or soon to be issued, patents & 16 patent applications. In addition to his technology experience, he has direct experience in strategic planning of corporate growth & development through in-house technology development, licensing opportunities, as well as mergers and acquisitions. Dr. Snodgrass is well published in the fields of molecular biology, blood development and stem cell sciences. Dr. Snodgrass was one of the early developers of the in vitro uses of the embryonic cell system for understanding genetic control of tissue development. Dr. Snodgrass has been a Director of VistaGen Therapeutics, Inc., since May 2011. Dr. Snodgrass has a Ph.D. in immunology from University of Pennsylvania.

Mr. Jerrold D. Dotson, CPA has been the Chief Financial Officer at VistaGen Therapeutics, Inc. since September 19, 2011. Mr. Dotson has been Secretary at VistaGen Therapeutics, Inc. since October 2013. Mr. Dotson has been Vice President at VistaGen Therapeutics, Inc. since February 2014. Mr. Dotson served as the Principal Accounting Officer at VistaGen Therapeutics, Inc. since September 19, 2011. Mr. Dotson served as Acting Chief Financial Officer at VistaGen Therapeutics, Inc. since September 19, 2011 until August 2012. He served as the Corporate Controller for Discovery Foods from January 2009 to September 2011 and served various positions in the finance and administration department of Calypte Biomedical Corporation from January 2000 to September 2008. Mr. Dotson served as Vice President of Finance and Administration of Calypte Biomedical Corp., since February 1, 2007 to September 2, 2008 and serves as its Secretary since 2001. Mr. Dotson served as Director of Finance at Calypte Biomedical Corp. from January 2000 to July 2005 and served as its Financial Consultant from August 2005 to January 2007. From 1988 to 1999, Mr. Dotson served various financial management positions, including Chief Financial Officer, of California & Hawaiian Sugar Company. Mr. Dotson served as a Consultant of Calypte Biomedical Corp. since September 2, 2008 Mr. Dotson is a Certified Public Accountant and has a BS degree in Business Administration with a concentration in Accounting from Abilene Christian College.

Mr. Mark Adrian McPartland has been Vice President of Corporate Development at VistaGen Therapeutics, Inc. since February 17, 2017. Mr. McPartland served as Vice President of Corporate Development & Investor Relations at VistaGen Therapeutics, Inc. since October 4, 2016 until February 17, 2017. Prior to joining VistaGen, Mr. McPartland served as Vice President of Corporate Development & Communications at Stellar Biotechnologies, Inc. from November 15, 2013 to September 29, 2016. Mr. McPartland served as Senior Vice President at Stellar Biotechnologies, Inc., until November 20, 2013. He joined Stellar with over 16 years experience in business development, capital markets advisory, corporate communications and C-suite consulting. Prior to joining Stellar, he served as Senior Vice President of MZ Group, a subsidiary of @titude Global. Mr. McPartland's background includes guiding the development and execution of corporate strategy for private and public companies at all stages of their commercial evolution, including early- and mid-stage biopharmaceutical entities. His experience prior to MZ Group includes Vice President and Partner at Alliance Advisors, LLC where he specialized in the implementation of capital markets strategy, market positioning and financial communications; and Regional Vice President of Hayden Communications, Inc. where he led investor relations and corporate communications programs for micro and small cap companies. Mr. McPartland holds a BS in Business Administration and Marketing from Coastal Carolina University.

Mark McPartland serves as the Vice President Corporate Development of VistaGen Therapeutics, Inc.. Mark started at VistaGen Therapeutics, Inc. in September of 2016. Mark currently resides in Wilmington, North Carolina Area.

Mark Smith serves as the Chief Medical Officer of VistaGen Therapeutics, Inc.. Mark started at VistaGen Therapeutics, Inc. in July of 2016. Mark currently resides in Greater Philadelphia Area.